Does BPC-157 Cause Cancer? The Angiogenesis Question, Explained

Written by Dr. Andrii Kaleniuk. Updated November 3, 2026.

No study has shown that BPC-157 causes cancer, but no study has shown that it doesn't, either. There are no long-term human data and no carcinogenicity studies, which are the standard tests for whether a substance causes cancer. The concern is mostly theoretical and comes from animal and cell experiments. In those experiments, BPC-157 promoted angiogenesis, the growth of new blood vessels, and in rat cells it raised the number of growth hormone receptors. Tumors need a blood supply to grow, so a substance that encourages new vessels could, in principle, help an existing cancer grow. That is why doctors generally tell people with cancer, or a history of cancer, to avoid it. Claims that it fights cancer are just as thin. Below we check each claim and cover its status with FDA, HHS and WADA as of November 2026.

BPC-157 is a short synthetic peptide, a chain of 15 amino acids, based on a fragment of a protein found in stomach juice. Most of its research comes from rats and cell cultures. The background is covered in what BPC-157 is, and the claimed effects are reviewed in BPC-157 benefits. It is not an approved medicine in the United States. A 2025 systematic review included 36 studies: 35 preclinical (animal or lab) and only 1 clinical, and found no clinical safety data.

The worry is not DNA damage, which no study suggests; it is growth signals. In lab and animal work, BPC-157 encouraged new blood vessels, increased growth hormone receptors on rat tendon cells and switched on signals that help cells move. These healing signals are the same kinds cancers use to grow and spread.

This idea is decades old. In 1971 the surgeon Judah Folkman argued in the New England Journal of Medicine that tumors cannot grow beyond a small size without new blood vessels, and that blocking those vessels could be a way to treat cancer. A 2000 Nature review by Carmeliet and Jain described angiogenesis as central to cancer and several other diseases, and blocking it is now an established cancer treatment. If blocking angiogenesis slows tumors, a peptide that promotes it might do the opposite. That is plausible but has never been tested with BPC-157.

The main study is from Hsieh and colleagues, published in the Journal of Molecular Medicine in 2017. They used chick embryo membranes, endothelial cells (which line blood vessels) and rats with blocked blood flow to a hind leg. BPC-157 increased VEGFR2, short for vascular endothelial growth factor receptor 2, at both the gene and protein level. VEGFR2 is the main receptor that tells blood vessel cells to grow. It did not raise VEGF-A, the growth factor that binds this receptor, but it switched on the VEGFR2–Akt–eNOS signaling chain.

A later study by the same group, published in Scientific Reports in 2020, found that BPC-157 affected blood vessel tone through the Src–Caveolin-1–eNOS pathway, which controls nitric oxide production. Nitric oxide widens blood vessels and supports their growth. The VEGF pathway also matters in cancer: in a 2004 study of human A375 melanoma cells grown in mice, making the tumor cells produce more VEGF increased tumor growth and spread. That study did not test BPC-157.

Two studies used rat Achilles tendon fibroblasts, the cells that build tendon. In a 2014 study in Molecules, BPC-157 at 0.1 to 0.5 micrograms per milliliter raised growth hormone receptor levels by up to about 7-fold by day 3. Adding growth hormone then made the cells multiply faster. A 2011 study in the Journal of Applied Physiology found that BPC-157 increased tendon cell migration and raised the activation of FAK and paxillin, two proteins that help cells attach and move, in a dose-dependent way.

For tendons these effects are useful (see BPC-157 before and after), but for cancer they raise questions. Growth hormone signaling and cell migration both play roles in how some tumors grow and spread. But these were rat tendon cells in a dish, not human or cancer cells: a reason for caution, not evidence of harm.

Only a little, mostly by the group that developed it:

We found no published study showing that BPC-157 makes tumors grow faster. But nobody appears to have run the key experiment: giving BPC-157 to animals with established tumors and measuring tumor growth and spread.

No. In 2025 the journal Pharmaceuticals published an exchange about this question. Sikiric and colleagues, the developers of BPC-157, argued that it has anti-tumor potential. Józwiak and colleagues replied that there are no published in vivo (living animal) data showing that BPC-157 reduces tumor volume or metastasis. They also said its pro-angiogenic activity is a plausible tumor-promoting risk. The cachexia work, they noted, addressed muscle wasting rather than tumor growth.

Some websites cite studies on tumor growth, tumor immune cells or liver cancer that we could not find in the published literature. Treat such claims as unverified.

Three small human reports have been published, all without a control group:

These studies were not designed to detect cancer. Cancers often take years to appear, and a few dozen people followed for weeks cannot reveal a small rise in risk. Short-term side effects that have been reported are covered in BPC-157 side effects. The honest summary is that the long-term human safety of BPC-157 is unknown.

Yes, and the difference matters. Causing cancer means damaging cells so that they become malignant, usually by harming DNA. Nothing in the BPC-157 research points to that. Promoting cancer means helping a tumor that already exists grow, get a blood supply or spread. The angiogenesis and growth hormone receptor findings point to this second possibility.

Many adults carry small undiagnosed tumors or precancerous changes, and people treated for cancer may have microscopic disease left. For them, a blood-vessel promoter is a bigger concern.

Its status changed several times in 2026. As of November 2026 (details in is BPC-157 legal):

Some groups have more to lose than others:

Gut-healing and oral-use claims are discussed separately in oral BPC-157. Stacking with TB-500 ( BPC-157 vs TB-500 and the Wolverine stack) adds a second unapproved peptide.

If you have already used BPC-157, stopping and telling your doctor is a reasonable step. No test shows whether it affected cancer risk, so keep up normal screening and report new symptoms promptly.

There is no evidence that BPC-157 causes cancer, but there is also no long-term human research that rules it out. The worry comes from animal and cell studies in which BPC-157 promoted new blood vessel growth and raised growth hormone receptors, two signals that tumors can exploit. No study shows it shrinks tumors either. As of November 2026 it remains unapproved by FDA and banned in sport. If you have or have had cancer, the cautious and sensible choice is to avoid it and talk to your doctor.

This article summarizes published research for general information and is not medical advice. Much of the BPC-157 research, including the anti-tumor claims, comes from the research group that developed the peptide.